论文部分内容阅读
对155例恶性肿瘤患者血清的GGT，CP，LD，ALP，α1-AT，AFU，AFP，CEA进行测定。结果：α1-AT测定值除血液病比正常参考值低外，其它癌症组均高于正常参考值的上限，表明α1-AT测定适用于多种癌症的检测。肝癌患者GGT，CP，α-AT，AFU，AFP活性显著升高，阳性率达52～91％。胰头癌除LD，CEA，AFP外其它5项指标升高显著。肺癌组CP，α1-AT，LD活性明显升高，阳性率在62．5～87．5％。消化道癌α1-AT，CEA增加，阳性率为62．3％和14％。鼻咽癌GGT，CP，α1-AT，AFU升高，阳性率分别是67，100，67，67％。乳腺癌CP和α1-AT升高，阳性率为67％。粒细胞白血病LD活性升高非常显著，阳性率为100％。
The serum GGT, CP, LD, ALP, α1-AT, AFU, AFP, and CEA were measured in 155 patients with malignant tumors. RESULTS: The determination value of α1-AT was lower than the normal reference value except for hematological diseases, and other cancer groups were higher than the upper limit of the normal reference value, indicating that the α1-AT assay is suitable for the detection of various cancers. The activity of GGT, CP, α-AT, AFU and AFP in patients with hepatocellular carcinoma was significantly increased, and the positive rate was 52 to 91%. In addition to LD, CEA, AFP, other five indicators of pancreatic head cancer increased significantly. The activities of α1-AT and LD in the lung cancer group were significantly increased, and the positive rate was between 62.5 and 87.5%. Gastrointestinal cancer α1-AT, CEA increased, the positive rate was 62.3% and 14%. Nasopharyngeal carcinoma GGT, CP, α1-AT, AFU increased, the positive rates were 67, 100, 67, 67% respectively. Breast cancer had elevated CP and α1-AT, with a positive rate of 67%. The increase of LD activity in granulocytic leukemia is very significant, with a positive rate of 100%.